To investigate radiation dose to testes delivered by radiolabeled anti-CD20 antibody and its effects on male sex hormone levels. METHODS: We evaluated dosimetry results for 67 male patients (54 ± 11 years old) with non-Hodgkin lymphoma who underwent myeloablative radioimmunotherapy (RIT) using 131I-tositumomab. In a subset of patients, male sex hormones were measured before and one year after the therapy. RESULTS: Absorbed dose to testes showed greater variability (range = 4.4 to 70.2 Gy) than did dose to lungs (9.5 to 28.4 Gy, p
Revised: November 7, 2012 |
Published: December 1, 2012
Citation
Hattori N., A.K. Gopal, A.T. Shields, D.R. Fisher, T. Gooley, J.M. Pagel, and O.W. Press, et al. 2012.131I-Tositumomab Myeloablative Radioimmunotherapy for Non-Hodgkin's Lymphoma: Radiation Dose to the Testes.Nuclear Medicine Communications 33, no. 12:1225-1231.PNNL-SA-86954.doi:10.1097/MNM.0b013e328358d34b